ELISA/assay

Apolipoprotein C3 (APOC3) ELISA Kit

MBS2020394

24-Strip-Wells

265 USD

ELISA Kit

Apolipoprotein C3 (APOC3) ELISA Kit

[Apolipoprotein C3 (APOC3)]

[Apo-C3; APOCIII; APOC-III]

[apolipoprotein C-III; Apolipoprotein C-III; apolipoprotein C-III; apolipoprotein C-III; Apolipoprotein C3]

[APOC3]

[APOC3; APOC3; HALP2; APOCIII; Apo-CIII; ApoC-III]

APOC3_HUMAN

Mouse

99

This assay has high sensitivity and excellent specificity for detection of Apolipoprotein C3 (APOC3). No significant cross-reactivity or interference between Apolipoprotein C3 (APOC3) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

Assay Type: Double-antibody Sandwich. Samples: Serum, Plasma, Tissue homogenates, Cell lysates, Cell culture supernates and Other Biological Fluids. Detection Range: 0.78-50ng/mL. Sensitivity: < 0.37ng/mL

Application: Enzyme-linked immunosorbent assay for Antigen Detection. Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Apolipoprotein C3 (APOC3) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Apolipoprotein C3 (APOC3) were tested on 3 different plates, 8 replicates in each plate. CV(%) =: SD/meanX100. Intra-Assay: CV<10%. Inter-Assay: CV<12%

Metabolic pathway; Endocrinology; Cardiovascular biology; Hepatology; Nutrition metabolism

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Apolipoprotein C3 (APOC3). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Apolipoprotein C3 (APOC3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Apolipoprotein C3 (APOC3), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm 10nm. The concentration of Apolipoprotein C3 (APOC3) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

4557323

NP_000031.1

NM_000040.1

P02656

10,852 Da

Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); HDL-mediated Lipid Transport Pathway (106158); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Pathway (477135); Metabolism Of Lipids And Lipoproteins Pathway (160976); PPAR Signaling Pathway (83042); PPAR Signaling Pathway (450)

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq, Jul 2008]

APOC3: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. Defects in APOC3 are the cause of hyperalphalipoproteinemia type 2 (HALP2). HALP2 is a condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels. Belongs to the apolipoprotein C3 family. Protein type: Secreted, signal peptide; Secreted; Lipid-binding. Chromosomal Location of Human Ortholog: 11q23.3. Cellular Component: extracellular space; chylomicron; early endosome; extracellular region. Molecular Function: lipase inhibitor activity; cholesterol binding; phospholipid binding; enzyme regulator activity. Biological Process: response to drug; response to peptide hormone stimulus; cholesterol metabolic process; phototransduction, visible light; regulation of Cdc42 protein signal transduction; lipoprotein metabolic process; cholesterol efflux; G-protein coupled receptor protein signaling pathway; cholesterol homeostasis; reverse cholesterol transport; triacylglycerol metabolic process; negative regulation of lipid catabolic process; phospholipid efflux; lipoprotein transport; triacylglycerol catabolic process; negative regulation of lipoprotein lipase activity; negative regulation of receptor-mediated endocytosis; negative regulation of lipid metabolic process; triacylglycerol mobilization; retinoid metabolic process; inflammatory response; response to nutrient; negative regulation of fatty acid biosynthetic process. Disease: Apolipoprotein C-iii Deficiency

24-Strip-Wells

265 USD

48-Strip-Wells

490

96-Strip-Wells

655

5x96-Strip-Wells

2660

10x96-Strip-Wells

4795